COVID-19 vaccine effectiveness
(Randomized evidence)
If you want to see all comparisons, please click here
ChAd/BNT-28 vs ChAd/ChAd-28
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
Forest plots
(last update: 2021-07-15)
Summary of findings
2021-07-26
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
ISRCTN69254139, EudraCT: 2020-005085-33 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Liu X, SSRN, 2021 Com-COV Full text Commentary Commentary Commentary Commentary |
RNA based vaccine |
ChAd/ChAd-28 BNT/BNT-28 |
ChAd/BNT-28 BNT/ChAd-28 |
RCTPhase 2 | Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK | N=463 |
Some concerns Details |
|